(22)For the active substances difenoconazole, diflufenican, extract from tea tree, flurochloridone and indolylbutyric acid, on 22 July 2021, 5 May 2021, 20 June 2024, 28 October 2024 and 3 April 2024, respectively, additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Commission Regulation (EU) 2018/605note, was requested by the Authority in consultation with the Member States pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012. The additional information for difenoconazole, diflufenican and flurochloridone was submitted by the applicants within the deadline given, and for extract from tea tree and indolylbutyric acid the submission is pending. The rapporteur Member States submitted the revised draft renewal assessment reports for diflufenican and flurochloridone to the Authority and the public consultations on them finished on 18 June 2024 and 3 June 2025, respectively. However, additional time is needed for the Authority to complete the evaluation and to finalise its conclusion for difenoconazole, diflufenican, extract from tea tree, flurochloridone and indolylbutyric acid, as well as for the Commission to adopt the ensuing risk management decision.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.